Bevacizumab Avastin®
The SHIKARI® Bevacizumab portfolio provides quantitative free-drug measurement, quantitative and qualitative anti-drug-antibody assays, and a target-capture neutralising-antibody assay for human serum or plasma.
Why Bevacizumab is relevant to biological-drug monitoring research
Bevacizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Bevacizumab is a humanised IgG1 monoclonal antibody that binds VEGF-A and inhibits VEGF-mediated angiogenic signalling. Source ↗
Approved Indications
EMA-authorised oncology uses include defined settings in metastatic colorectal cancer, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian/fallopian-tube/primary peritoneal cancer and cervical cancer, generally in specified combinations. EMA source ↗
Regimen-Specific Exposure
FDA population-PK modelling provides an exposure reference for a 5 mg/kg every-two-weeks regimen:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Four verified Bevacizumab research assays
Ligand-binding, sandwich-principle ELISA for quantitative analysis of free bevacizumab capable of binding VEGF-A in human serum or plasma.
Quantitative ELISA for anti-bevacizumab antibodies in human serum or plasma, including the assay-specific confirmation-reagent procedure.
Qualitative ELISA for positive or negative assessment of anti-bevacizumab antibodies in human serum or plasma according to assay-specific cut-off interpretation.
Target-capture immunoassay for qualitative detection of free neutralising antibodies to bevacizumab, using positive, negative, cut-off and non-neutralising-antibody controls.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-BEVA | BEV-FD-AA | Quantitative | Free bevacizumab | Human serum / plasma | 10 µL | 70 min | LOD 30 ng/mL; LOQ 30 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATB | BEV-QNS-AA | Quantitative | Anti-bevacizumab antibodies | Human serum / plasma | 20 µL | 140 min | LOD 7.5 ng/mL; LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATB | BEV-QLS-AA | Qualitative | Anti-bevacizumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® T-CAP NAb™ — Bevacizumab | BEV-TCAP-NAb-AA | Qualitative | Free neutralising antibodies to bevacizumab | Human serum / plasma | 10 µL | 140 min | LOD 20 ng/mL; qualitative | 96 | 6 months | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Publications Using SHIKARI® Bevacizumab Kits 13
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Planning a Bevacizumab research study?
Matrix Biotek can help identify the appropriate Bevacizumab assay and prepare regional quotation and delivery information.